# First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

> **NCT06217822** · PHASE1 · RECRUITING · sponsor: **Bayer** · enrollment: 198 (estimated)

## Conditions studied

- Advanced Metastatic Castration-resistant Prostate Cancer
- Prostate Specific Membrane Antigen (PSMA) Expression

## Interventions

- **DRUG:** 225Ac-PSMA-Trillium (BAY3563254)

## Key facts

- **NCT ID:** NCT06217822
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-07
- **Primary completion:** 2028-11-26
- **Final completion:** 2032-05-28
- **Target enrollment:** 198 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06217822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06217822, "First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06217822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*